EGFR negative

P1/2, N=420, Recruiting, BioNTech SE

P2, N=28, Not yet recruiting, Shanghai Juncell Therapeutics

In PREDIX LumB patients with estrogen receptor positive and human epidermal growth factor receptor negative (ER + /HER2-) breast cancer > 20 mm and/or with lymph node metastasis were randomized 1:1 to receive either paclitaxel weekly for 12 weeks followed by palbociclib and endocrine therapy for 12 weeks (arm A), or the reverse sequence (arm B). The predictive signature was independently validated in the CORALLEEN trial (pinteraction=0.048). Clinicaltrials.gov identifier: NCT02603679.

Overall, our results suggest that multiple pathways of EV biogenesis may operate in glioma cells resulting in formation of complex EV landscapes consisting of EGFR-positive and EGFR-negative EV subsets. This heterogeneity may have important implications for EV functions and EV-based diagnostics.

In ER-positive, HER2-negative breast cancer, clinical responses and post-NAC Ki-67 were significant prognostic factors in patients aged ≤50 years but not in older patients. These findings highlight the need for tailored therapeutic approaches that consider age-specific prognostic differences.

P=N/A, N=15, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting

P1, N=254, Recruiting, Shanghai Henlius Biotech | Active, not recruiting --> Recruiting

P=N/A, N=3883, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed

P2, N=38, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

LM has been attracting attention, possibly due to the long-term survival achieved by EGFR-tyrosine kinase inhibitors. Additional information is required to clarify the risk of LM.

In vivo, targeted treatment suppressed tumor progression, yielding a mean tumor volume of 330 mm3, compared to 675 mm3 and 770 mm3 in untargeted and control groups, respectively, without observable liver or kidney toxicity. These results highlight the therapeutic potential of peptide-tagged cubosomes for the selective treatment of EGFR-expressing cancers.

In our cohort with 5-y survival data, BCT is a safe option for women aged 40 y and under who are diagnosed with breast cancer. Despite no survival benefit, young women with breast cancer in our cohort underwent mastectomy more often than lumpectomy. Importantly, most recurrences were distant metastases, suggesting that local therapy choice is less relevant to outcome.